NADH/chronic fatigue study
This article was originally published in The Tan Sheet
In a Georgetown University trial involving 26 patients, eight (31%) reported "significant" improvement in their chronic fatigue syndrome symptoms while taking NADH (nicotinamide adenine dinucleotide), according to Linda Forsyth, MD, et al. No adverse effects were observed in the patients during the 12-week trial period. The results of the double-blind, placebo-controlled trial were published in the February Annals of Allergy, Asthma and Immunology. The researchers plan to conduct further studies on the ingredient that will be open-label and in a larger patient population. The product used in the study, Enada NADH supplement, is manufactured by Menuco and distributed by Natrol
You may also be interested in...
Perrigo promotes in pricing, planning
Combe sells most of its OTC brands
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC